Skip to content
Trouver

Medicine in DR Congo · official US FDA label

PAPAVERINE 40 mg

Papavérine (papaverine) · comprimé

Authorized in DR Congo

Want to buy it?

Not in stock in our pharmacies right now. Trouver shows when it is back near you. The reservation pages are in French.

See the pharmacies

This is a US label.

The official US FDA label for papaverine (published as PAPAVERINE HYDROCHLORIDE), effective July 27, 2026, describes products sold in the United States. The medicine sold in DR Congo may differ in strength, form or approved uses: ask a pharmacist or a doctor.

Official US FDA label for papaverine

Data provided by the U.S. Food and Drug Administration (openFDA), unchanged. The full label on DailyMed.

Uses

INDICATIONS AND USAGE Papaverine is recommended in various conditions accompanied by spasm of smooth muscle, such as vascular spasm associated with acute myocardial infarction (coronary occlusion), angina pectoris, peripheral and pulmonary embolism, peripheral vascular disease in which there is a vasospastic element, or certain cerebral angiospastic states; and visceral spasm, as in ureteral, biliary, or gastrointestinal colic.

Dosage

US dosage, for products sold in the United States. For a medicine bought in DR Congo, follow its box, its leaflet or your pharmacist.

DOSAGE AND ADMINISTRATION Papaverine Hydrochloride may be administered intravenously or intramuscularly. The intravenous route is recommended when an immediate effect is desired, but the drug must be injected slowly over the course of 1 or 2 minutes to avoid uncomfortable or alarming side effects. Parenteral administration of papaverine hydrochloride in doses of 1 to 4 mL is repeated every 3 hours as indicated. In the treatment of cardiac extrasystoles, 2 doses may be given 10 minutes apart.

Side effects

ADVERSE REACTIONS The following side effects have been reported: general discomfort, nausea, abdominal discomfort, anorexia, constipation or diarrhea, skin rash, malaise, vertigo, headache, intensive flushing of the face, perspiration, increase in the depth of respiration, increase in heart rate, a slight rise in blood pressure, and excessive sedation. Hepatitis, probably related to an immune mechanism, has been reported infrequently. Rarely, this has progressed to cirrhosis.

Where to find it in DR Congo

Not in stock in our pharmacies right now

Stock changes with every sale. Search by substance: a medicine with the same composition may be available.

Composition

SubstanceStrengthATC code
Papaverine chlorhydrate (papaverine)40 mg—

Marketing authorization in DR Congo

From the register of the ACOREP (the Congolese pharmaceutical regulatory authority).

  • Authorization number

    ACRP/CAB/DG/D11/00/A/MH/2616/2025

    Valid from June 3, 2025 until June 3, 2030

    Holder
    CAISA PHARMA INTERNATIONAL SARL 1861,Av.General Bobozo Q/Kingabwa C/ Limete Kinshasa
    Manufacturer
    CAISA PHARMA INTERNATIONAL SARL 1861,Av.General Bobozo Q/Kingabwa C/ Limete Kinshasa
    Country
    Congo (la République démocratique du)

Sources

  • ●Labels: U.S. Food and Drug Administration, openFDA (public domain). Data provided by the U.S. Food and Drug Administration (openFDA), unchanged. DailyMed.
  • ●English names of substances: RxNorm, U.S. National Library of Medicine.
  • ●Marketing authorizations: register of the ACOREP, DR Congo, version of February 4, 2026.

Public information, for reference only: it does not replace the advice of a pharmacist or a doctor. Vimpia writes nothing about how to use a medicine and translates nothing: the label is the US FDA's, unchanged; names, composition and authorizations come from the official sources above.